Metastatic basal cell carcinoma: complete response to chemotherapy and associated pure red cell aplasia.

Abstract

Basal cell carcinoma (BCC) is usually a benign and indolent cancer cured in greater than 95 percent of cases. Nevertheless, it can be locally destructive or occasionally metastasize to distant organs. We report a case of BCC metastatic to the lungs, occurring 17 years after the primary BCC was noticed, that responded to carboplatin and paclitaxel on 3 occasions. The patient also developed pure red cell aplasia (PRCA). Work-up did not reveal underlying thymoma or infectious, rheumatologic, or lymphoproliferative disorders. Parvovirus serologies were negative, and antibodies against erythropoetin were not detected. There was no history of exposure to drugs associated with PRCA. Bone marrow biopsy on 2 different occasions did not show evidence of myelodysplasia. PRCA may represent an unusual paraneoplastic syndrome associated with BCC as reported with other carcinomas. This is the first report of PRCA associated with metastatic BCC or the drugs carboplatin and paclitaxel, which were used to treat it. The literature on chemotherapy for metastatic BCC is reviewed.

• Authors: Benedito A Carneiro, William G Watkin, Uday K Mehta, Bruce E Brockstein
• Journal: Cancer investigation (Cancer Invest) 2006 Jun-Jul Vol. 24 Issue 4 Pg. 396-400 ISSN: 0735-7907 [Print] England
• PMID: 16777692 (Publication Type: Case Reports, Journal Article)

Chemical References

• Carboplatin
• Paclitaxel

Topics

• Aged
• Antineoplastic Combined Chemotherapy Protocols (therapeutic use)
• Carboplatin (administration & dosage)
• Carcinoma, Basal Cell (drug therapy, secondary)
• Humans
• Lung Neoplasms (drug therapy, secondary)
• Male
• Paclitaxel (administration & dosage)
• Paraneoplastic Syndromes (complications)
• Red-Cell Aplasia, Pure (etiology, pathology)
• Skin Neoplasms (pathology)